Haeyoung Kim; Su SSan Kim; Ji Sung Lee; Jae Sun Yoon; Hyun Jo Youn; Hyukjai Shin; Jeong Eon Lee; Se Kyung Lee; Il Yong Chung; So-Youn Jung; Young Jin Choi; Jihyoung Cho; Sang Uk Woo; Korean Breast Cancer Society

doi:10.4143/crt.2022.410

Articles

Page Path: HOME > Cancer Res Treat > Volume 55(2); 2023 > Article

Original Article Breast cancer Epidemiology of Second Non-breast Primary Cancers among Survivors of Breast Cancer: A Korean Population–Based Study by the SMARTSHIP Group: Haeyoung Kim¹, Su SSan Kim², Ji Sung Lee³, Jae Sun Yoon⁴, Hyun Jo Youn⁵, Hyukjai Shin⁶, Jeong Eon Lee⁷, Se Kyung Lee⁷, Il Yong Chung⁸, So-Youn Jung⁹, Young Jin Choi¹⁰, Jihyoung Cho¹¹, Sang Uk Woo¹², Korean Breast Cancer Society; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2023;55(2):580-591.
DOI: https://doi.org/10.4143/crt.2022.410
Published online: December 27, 2022

¹Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

³Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁴Department of Biostatistics, Korea University, Seoul, Korea

⁵Department of Surgery, Research Institute of Clinical Medicine, Jeonbuk National University Hospital, Jeonbuk National University and Biomedical Research Institute, Jeonju, Korea

⁶Department of Surgery, Myongji Hospital, Seonam University College of Medicine, Goyang, Korea

⁷Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁸Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁹Center for Breast Cancer, National Cancer Center, Goyang, Korea

¹⁰Department of Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea

¹¹Department of Surgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea

¹²Department of Surgery, Korea University College of Medicine, Seoul, Korea

Correspondence: Su SSan Kim, Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea,
Tel: 82-2-3010-5680, Fax: 82-2-3010-6950, E-mail: watermountain@hanmail.net

* An early version of this study has been presented at the San Antonio Breast Cancer Symposium in December 2021.

• Received: June 28, 2022 • Accepted: December 26, 2022

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,786 Views
94 Download
2 Web of Science
2 Crossref
1 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This study aimed to evaluate the incidence and prognosis of second non-breast primary cancer (SNBPC) among Korean survivors of breast cancer.
Materials and Methods
Data from the Korean National Health Insurance Service were searched to identify women who received curative surgery for initial breast cancer (IBC) between 2003 and 2008 (n=64,340). Among them, patients with the following characteristics were excluded: other cancer diagnosis before IBC (n=10,866), radiotherapy before IBC (n=349), absence of data on sex or age (n=371), or male (n=248). Accordingly, data of 52,506 women until December 2017 were analyzed. SNBPC was defined as a newly diagnosed SNBPC that occurred 5 years or more after IBC diagnosis.
Results
The median follow-up time of all patients was 12.13 years. SNBPC was developed in 3,084 (5.87%) women after a median of 7.61 years following IBC diagnosis. The 10-year incidence of SNBPC was 5.78% (95% confidence interval [CI], 5.56 to 6.00). Higher SNBPC incidence was found in survivors with the following factors: old age at IBC diagnosis, low household income, and receiving combined chemotherapy with endocrine therapy, whereas receiving radiotherapy was related to a lower incidence of SNBPC (hazard ratio, 0.89; p < 0.01). Among the patients with SNBPC, the 5-year survival rate was 62.28% (95% CI, 65.53 to 69.02).
Conclusion
Approximately 5% of breast cancer survivors developed SNBPC within 10 years after IBC diagnosis. The risk of SNBPC was associated with patient’s age at IBC diagnosis, income level, and a receipt of systemic treatments.
Key words: Breast neoplasms, Cancer survivors, Neoplasms, Second primary, Epidemiology, Incidence, Risk factors

Introduction

Breast cancer is the most common cancer worldwide, accounting for 11% of new cancer cases globally as of 2020 [1]. In Korea, the incidence of breast cancer is the highest among female cancers and has been continuously increasing in recent decades [2,3]. More than 90% of new breast cancer cases in Korea are diagnosed at the locoregional stage [4]. The early stage of diagnosis and advances in treatment have improved survival outcomes in patients with breast cancer [2]. According to recent studies on cancer statistics in Korea, the 5-year relative survival rate for breast cancer was estimated to be 93.2% among women newly diagnosed with breast cancer between 2013 and 2017 [2,4]. Consequently, there are an increasing number of survivors of breast cancer, with over 122,000 women who survived more than 5 years after diagnosis, as of 2018 in Korea [4]. In addition, survivors of breast cancer constitute more than 20% of all cancer survivors among Korean women [3]. Given the growing number of survivors and chronic conditions of breast cancer, management of lifelong medical issues is a requirement for optimal long-term care for survivors of breast cancer.

The development of second non-breast primary cancer (SNBPC) is one of the essential issues that may be encountered by survivors of breast cancer [5]. Previous studies have shown that various types of SNBPC occurred after breast cancer treatment [6–13]. Moreover, the risk of developing SNBPC among survivors of breast cancer significantly exceeds that in women without cancer in the general population [8,11,14]. Furthermore, patients with SNBPC may come across complicated medical issues caused by a previous treatment for breast cancer. Considering the elevated risk of SNBPC and the presumable need for elaboration of SNBPC management, it is necessary to know the incidence and prognosis of SNBPC in survivors of breast cancer in each population. Unlike other populations in whom information on SNBPC has been well described, little is known about Korean population data regarding SNBPC in survivors of breast cancer [11,12].

This study was conducted to estimate the incidence of SNBPC and evaluate the prognosis after SNBPC diagnosis among survivors of breast cancer in Korea. To obtain complete population data on SNBPC, we analyzed claims data from the National Health Insurance Service (NHIS) which contains information on various medical utilization and mortality for the whole population of South Korea [15]. Based on this analysis, we aimed to establish knowledge on SNBPC in Korean women and thus facilitate improved management of survivors of breast cancer.

Materials and Methods

1. Data source

This retrospective observational population-based study was conducted by reviewing claims data in the NHIS database. The NHIS database encompasses the Korean population’s longitudinal claims data since 2002, regarding healthcare utilization, sociodemographic variables, cancer information, and mortality [15]. Cancer cases were searched using the International Classification of Disease, 10th edition (ICD-10). Breast cancer surgery and adjuvant therapies (chemotherapy, endocrine therapy, and radiotherapy) initiated within 1 year after breast surgery were searched using codes described in S1 Table. Data collection was performed between January 2021 and April 2021, with a call for NHIS data between January 2003 and December 2017. According to the institutional review board at Samsung Medical Center, the current study was exempt from approval from an ethics committee since the data were de-identified and publicly open to use.

2. Patients

To construct patients’ cohort for SNBPC analysis, we extracted data of breast cancer patients who received curative surgery between 2003 and 2008 (n=64,340). Among the patients, individuals with the following factors were excluded from the cohort: history of other cancer diagnoses before breast cancer surgery (n=10,866), having radiotherapy before breast cancer surgery (n=349), absence of data on sex or age (n=371), or male (n=248). Accordingly, we found 52,506 women with breast cancer who were fit to represent a cohort of locoregional breast cancer treated between 2003 and 2008. The flow chart of the current study is shown in Fig 1. The characteristics of the 52,506 patients are shown in Table 1.

SNBPC was defined as a newly diagnosed non-breast primary cancer that occurred 5 years or more after initial breast cancer (IBC) diagnosis. Metastatic cancers were excluded from SNBPC by disregarding patients with disease codes C77, C78, and C79. To assess whether types of SNBPC were associated with breast cancer radiotherapy, SNBPC was classified into one of the following categories depending on proximity from the breast: category A - cancer in the intrathoracic organs, thyroid, esophagus, or stomach; category B - cancer of hematopoietic or lymphoid tissue; and category C - cancer in the head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs.

3. Statistical analysis

Comparisons of variables between different groups were conducted by using the chi-square test, Student’s t test, or Wilcoxon rank sum test according to the type of variable. The patient’s follow-up was initiated from the date of breast cancer diagnosis and lasted until death or December 31, 2017, whichever occurred first. SNBPC incidence was determined according to intervals from the date of IBC diagnosis to the dates of SNBPC diagnosis, death, or December 31, 2017. In patients with SNBPC, post-SNBPC survival was decided as the interval between the date of SNBPC diagnosis and the date of death or December 31, 2018. The event probability of SNBPC and overall survival (OS) probability was calculated by using the Kaplan-Meier method. A comparison of survivals among groups with different variables was performed using the log-rank test or Cox proportional hazards regression model. The p-values of < 0.05 were considered statistically significant. Statistical analyses were performed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC).

Results

The median follow-up time of all 52,506 patients was 12.13 years (interquartile range [IQR], 10.63 to 13.92 years). SNBPC was developed in 3,084 women (5.87%) after a median duration of 7.61 years (IQR, 6.22 to 9.31 years) following an IBC diagnosis. More than 33% of SNBPC was found 8–11 years after IBC diagnosis. The largest proportion of patients with SNBPC had been 40–59 years old when the patients were diagnosed with IBC. Thyroid cancer was the most frequent type of SNBPC, followed by gastrointestinal and hepatobiliary cancer. Details of the patients with SNBPC are presented in Table 2.

Factors were compared depending on receipt of radiotherapy to evaluate the influence of breast cancer radiotherapy on the development of SNBPC. Women given radiotherapy for IBC were more likely to be young, at a high-income level, and treated with combined systemic therapies for breast cancer than those without radiotherapy. The frequency of SNBPC was significantly lower in women with breast cancer radiotherapy than in those without radiotherapy (5.34% vs. 6.50%, p < 0.001). The proportion of SNBPC that developed 11 years or more after IBC diagnosis was lower in the radiotherapy group than in the non-radiotherapy group (8.31% vs. 11.14%) when it was estimated among patients with SNBPC. Nonetheless, types of SNBPC were not dependent on breast cancer radiotherapy. Details are shown in Table 3.

The 10-year incidence rate of SNBPC development was 5.78% (95% confidenc interval [CI], 5.56 to 6.00). There was a significant difference in SNBPC incidence depending on the patient’s characteristics including age, income levels, types of adjuvant systemic treatment, and receipt of radiotherapy for IBC treatment. A higher SNBPC incidence was noted in survivors with the following factors: old age at IBC diagnosis, low household income, receiving chemotherapy along with endocrine therapy, and no administration of radiotherapy for IBC. In Table 4, further information on the incidence rate of SNBPC is described.

Among the patients with SNBPC, the 5-year OS rate was 62.28% (95% CI, 65.53 to 69.02) after a median follow-up of 3.82 years (95% CI, 2.09 to 5.98) following SNBPC diagnosis. The 5-year OS was inferior in patients with the following characteristics than in those without these factors: old age at IBC diagnosis (≥ 60 years old), low household income, and combined modality of systemic therapy for breast cancer. Nevertheless, receipt of radiotherapy was not associated with OS following SNBPC diagnosis. Table 5 shows the details of OS in SNBPC patients.

Discussion

This study found that the 10-year incidence rate of SNBPC was 5.78% among 52,506 Korean women who had curative surgery for breast cancer between 2003 and 2008. Old age at IBC diagnosis, low household income, and receiving combined chemotherapy with endocrine therapy was associated with a higher SNBPC incidence. In comparison, an administration of breast cancer radiotherapy was related to a lower incidence of SNBPC. Among the patients with SNBPC, thyroid cancer was the most frequent type of cancer. The distribution of SNBPC types was not different according to breast cancer radiotherapy receipt. In addition, less than 68% of patients with SNBPC were estimated to survive 5 years after SNBPC diagnosis. Taken together, the results of this study provide essential information on SNBPC in Korean survivors of breast cancer.

The incidence of SNBPC has been evaluated in several studies from diverse populations [6–14,16–19]. The studies examined databases from various sources, including nationwide population-based data, regional registries, or institutional cohorts, to obtain comprehensive information on SNBPC (Table 6). Given that contralateral breast cancer is the most frequent type of subsequent cancer in survivors of breast cancer [14], researchers in some previous studies have analyzed the incidence of subsequent cancers including the cases with contralateral breast cancer [13,14,17]. Accordingly, the incidence rates of subsequent cancer varied between 2.1% and 12.3% Table 6. However, when the evaluation was focused on SNBPC cases, approximately 2.1%–8.2% of survivors of breast cancer were found to encounter SNBPC within a decade after primary breast cancer diagnosis [6–8,18,19]. In the current study, we found that Korean survivors of breast cancer exhibited a similar incidence of SNBPC compared to those in other populations. Since the SNBPC incidence increases with time after IBC treatment, it is necessary to follow up the cohort further to understand the epidemiologic characteristics of SNBPC among Korean survivors of breast cancer comprehensively [8,13].

The relative risk for SNBPC depends on several factors including age at IBC diagnosis, types of adjuvant treatment, and molecular subtypes of IBC [11,12,14,16]. Among the known risk factors, young age at IBC diagnosis, usually defined as < 50 years old, has been analyzed as an important contributor to excessive risk of SNBPC in several studies [6,8,11,14]. In those studies, the relative risk of SNBPC was estimated with a standardized incidence ratio (SIR) [8,11,14] or an adjusted hazard ratio (AHR) [6]. The SIR or AHR was calculated as the ratio of SNBPC incidence among survivors of breast cancer to the incidence of cancers among the cancer-free general population. According to previous studies, the SIR of SNBPC ranged between 1.47 and 1.77 among survivors whose IBC was diagnosed at a young age, while it was between 1.04 and 1.20 among survivors whose IBC was detected at old age [8,11,14]. The high SIR of SNBPC among young survivors of breast cancer is likely to result from combined effects, including cancer susceptibility in young breast cancer survivors and low cancer incidence in healthy young women in the general population. Nonetheless, in another aspect, the absolute incidence of SNBPC increased with the patients’ age at IBC diagnosis [6,8,13,18]. For example, in a study by Silverman et al. [8], the 5-year incidence of SNBPC was higher in women ≥ 50 years old at IBC diagnosis than in those < 50 years old. (5.1% vs. 2.2%). Similarly, our Korean population data shows that the 10-year SNBPC rate was 8.51% for survivors whose IBC was diagnosed at ≥ 60 years of age, while it was between 4.61% and 5.32% for survivors diagnosed at < 60 years of age. These findings suggest that old age is an important contributor to the enhanced risk of SNBPC.

Radiotherapy has been considered an important influencing factor for SNBPC development [12]. Several studies have shown that breast cancer radiotherapy was associated with an elevated risk of SNBPC [6,7,10,12,13,17]. In particular, the studies indicated that irradiated survivors of breast cancer had a higher incidence of SNBPC in the following cancer types compared to non-irradiated survivors: lung cancer [10,12,13,17,18], esophageal cancer [7,12], leukemia [9,13], soft tissue sarcoma [10,12,18], or all types of SNBPC at large [6,12]. However, even if multiple studies have suggested a hazardous effect of radiotherapy in terms of SNBPC development, several controversies remain regarding the interpretation of the results. First of all, the authors of the previous studies analyzed data from outdated cohorts. For instance, in a meta-analysis exhibiting a radiotherapy-related risk of SNBPC, the authors analyzed 13 studies on patients with breast cancer treated between 1954 and 2007 [12]. Radiotherapeutic technologies had been considerably improved during the previous decades, delivering focused radiation to the target more accurately, with minimizing radiation to the surrounding normal organs [20]. Therefore, it may be less likely that the risk of SNBPC is influenced by radiotherapy administered to the breast and regional nodes in individuals treated with modern radiotherapy techniques. It is necessary to assess the influence of radiotherapy on SNBPC in patients treated in recent years to overcome the problems in the literature. Therefore, we sought the incidence of SNBPC among patients treated with curative surgery for breast cancer between 2003 and 2008. Since the women included in our study had a median follow-up time of more than 12 years, our data is thought to be appropriate to update information on the association between radiotherapy and SNBPC development. Unlike the previous reports, we found that breast cancer radiotherapy was associated with decreased incidence of SNBPC. This result suggests that radiotherapy is not related to the elevation of SNBPC risk in Korean survivors of breast cancer. In another respect, however, the result may be attributable to the characteristics of irradiated patients in our cohort, which include a lower proportion of patients with old age-onset breast cancer and poor income in comparison to unirradiated patients. Given that variables such as old age and low household income were significantly associated with high SNBPC incidence in our analysis, the different distribution of the variables between irradiated and unirradiated patients may have affected the result. Aside from these risk factors, there might be other variables that possibly biased the impact of radiotherapy on SNBPC development. Therefore, it is necessary to include other probable risk factors for SNBPC to evaluate the association more accurately between radiotherapy and SNBPC development in future studies.

Combined adjuvant systemic treatment integrating chemotherapy and endocrine therapy was associated with higher SNBPC incidence in our study. Considering that the treatment usually has been given to the patients with advanced hormone-responsive breast cancer, it can be postulated that the stage or subtype of IBC might have affected the risk of SNBPC. In addition, the medications per se could have influenced the development of SNBPC. In a study by Sung et al. wherein the incidence of subsequent cancers among survivors of breast cancer was compared to that in the U.S. general population, the relative risk and subsequent cancer types were associated with hormone receptor (HR) status of IBC, with the SIR of 1.20 in HR-positive IBC and SIR of 1.44 in HR-negative IBC. The authors also showed complex interactions between types of subsequent cancers and the HR status of IBC [21]. Similarly, there were potentially some associations between the HR status of IBC and SNBPC development in survivors of Korean breast cancer. However, since the current analysis was conducted using insurance claims data, we could not obtain pathological data on IBC. Therefore, further studies incorporating clinicopathological data are required to examine unbiased associations between types of adjuvant systemic therapies and the SNBPC development.

Poor household income was associated with high SNBPC incidence in our study. Furthermore, survivors with poor income showed an inferior survival rate after SNBPC diagnosis than those with other income levels. In the Korean public health care system, the medical expenses of individuals at the lowest-income level are supported by the Medical Aid program, covering approximately 3% of the Korean population [22]. The Medical Aid beneficiaries have higher frequencies of chronic disease, unemployment, and old age than those in other income groups. Moreover, individuals at the lowest-income level are more likely to face difficulties in taking efficient medical services than those at a better income level [22]. The socio-economic and health-related factors seem to induce the development of SNBPC and cause poor prognosis after SNBPC diagnosis in survivors at the lowest-income level.

In this study, we examined epidemiologic characteristics of SNBPC in Korean survivors of breast cancer based on insurance claims data of the NHIS. Given that the NHIS contains data on medical service utilization in almost all Koreans, the current study is thought to provide comprehensive information on SNBPC among Korean survivors of breast cancer. However, there are limitations to this study. Firstly, since we used insurance claims data, clinic-pathologic information on IBC was not available for analysis. In addition, information on radiotherapy such as radiation dose and field could not be evaluated by using the claims data. Importantly, survivors developing sarcoma in the irradiated breast might not have been defined as SNBPC since we excluded patients with subsequent cancer in the breast based on disease codes in insurance claim data. Furthermore, health care services not covered by the NHIS were not included in this analysis. Therefore, patients treated with systemic agents uncovered by the public insurance were not counted as chemotherapy recipients in our study. Notwithstanding these limitations, this study provides valuable population-based information on the incidence and prognosis of SNBPC in Korean survivors of breast cancer. Moreover, the current study updates knowledge of SNBPC by analyzing data of patients who were treated in reasonably recent years with long-term follow-up. The basic facts on SNBPC are expected to be used to enhance an individual’s information level and assist patients’ education for Korean survivors of breast cancer.

In conclusion, approximately 5% of breast cancer survivors developed SNBPC within 10 years after IBC diagnosis. The risk of SNBPC was associated with patient’s age at IBC diagnosis, income level, and a receipt of systemic treatments. This study presents population-based information on SNBPC among Koran survivors of breast cancer. These basic facts need to be considered for a survivorship care plan in Korea.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2022-410-Supplementary-Table-1.pdf

NOTES

Ethical Statement

According to the institutional review board at Samsung Medical Center (SMC 2018-11-010), the current study was exempt from approval from an ethics committee since the data are de-identified and publicly open to use.

Author Contributions

Conceived and designed the study: Kim H, Kim SS.

Data collection: Lee JS, Yoon JS.

Contributed data or analysis tools: Youn HJ, Shin H, Lee JE, Lee SK, Chung IY, Jung SY, Choi YJ, Cho J, Woo SU.

Performed the analysis: Lee JS, Yoon JS, Kim H.

Wrote the paper: Kim H.

Review and comments: Kim SS, Lee JS, Youn HJ, Shin H, Lee JE, Lee SK, Chung IY, Jung SY, Choi YJ, Cho J, Woo SU.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by the research grant of the Korean Breast Cancer Society.

Fig. 1

Flowchart of the study. The second non-breast primary cancer (SNBPC) was defined as newly diagnosed non-breast primary cancer that occurred 5 years or more after an initial breast cancer diagnosis. ^a)Data on mortality were available until December 2018.

Table 1

Cohort’s characteristics (n=52,506)^a)

Variable	No. of patients (%)
Age at BC diagnosis (yr)
< 30	988 (1.9)
30–39	7,881 (15.0)
40–59	34,616 (65.9)
≥ 60	9,021 (17.2)
Level of household income
Medicare	1,156 (2.2)
Top 11%–100%	42,131 (80.2)
Top 1%–10%	8,492 (16.2)
Not available	727 (1.4)
Adjuvant systemic treatment for primary BC
None	5,750 (10.9)
Chemotherapy	12,482 (23.8)
Endocrine therapy	10,537 (20.1)
Chemotherapy and endocrine therapy	23,737 (45.2)
Radiotherapy for primary BC
None	24,322 (46.3)
Yes	28,184 (53.7)

BC, breast cancer.

^a) Characteristics of women included in this study. The patients received curative treatments for invasive BC between January 2003 and December 2008.

Table 2

Details of women who developed second non-breast primary cancer (n=3,084)

Variable	No. of patients (%)
Interval between BC diagnosis and SNBPC diagnosis (yr)
≥ 5 and < 8	1,736 (56.3)
≥ 8 and < 11	1,047 (33.9)
≥ 11 and < 14	301 (9.8)
Types of SNBPC
Head and neck cancer	79 (2.6)
Gastrointestinal cancer	580 (18.8)
Hepatobiliary cancer	385 (12.5)
Thoracic cancer	374 (12.1)
Gynecological cancer	394 (12.9)
Urologic cancer	78 (2.5)
Brain cancer	97 (3.2)
Thyroid cancer	581 (18.9)
Bone/Soft tissue/Nerve cancer	137 (4.4)
Skin cancer	130 (4.2)
Lymphoma or leukemia	126 (4.1)
Others	118 (3.8)
Category of SNBPC^a)
Category A	615 (19.9)
Category B	126 (4.2)
Category C	2,343 (75.9)
Age at primary BC diagnosis (yr)
< 30	46 (1.5)
30–39	412 (13.4)
40–59	1,906 (61.8)
≥ 60	720 (23.5)
Level of household income at primary BC diagnosis
Medical Aid Program	79 (2.6)
Top 11%–100%	2,452 (80.5)
Top 1%–10%	517 (16.9)
Adjuvant systemic treatment for primary BC
None	315 (10.2)
Chemotherapy alone	679 (22.1)
Endocrine therapy alone	608 (19.7)
Chemotherapy and endocrine therapy	1,482 (48.1)
Radiotherapy for primary BC
None	1,580 (51.2)
Yes	1,504 (48.8)

BC, breast cancer; SNBPC, second non-breast primary cancer.

^a) Category A: cancer in the intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in the head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs.

Table 3

Comparisons of patient’s characteristics according to receipt of breast cancer radiotherapy

Variable	Among all patients				Among patients with SNBPC
Variable	Total (n=52,506)	RT (+) (n=28,184)	RT (−) (n=24,322)	p-value	Total (n=3,084)	RT (+) (n=1,504)	RT (−) (n=1,580)	p-value
FU (yr)	12.13 (10.63–13.92)	11.88 (10.56–13.55)	12.47 (10.79–14.28)	< 0.001	12.27 (10.44–14.23)	11.88 (10.32–13.95)	12.59 (10.63–14.49)	< 0.001
Age (yr)	49.14±10.71	47.88±9.52	50.59 (11.77)	< 0.001	50.68±11.13	48.95±10.57	52.32±11.4	< 0.001
Age at BC diagnosis (yr)
< 30	988 (1.9)^a)	498 (1.8)	490 (2.0)	< 0.001	46 (1.5)^b)	34 (2.3)	12 (0.8)	< 0.001
30–39	7,881 (15.0)	4,559 (16.2)	3,322 (13.7)		412 (13.4)	241 (16.0)	171 (10.8)
40–59	34,616 (65.9)	19,605 (69.5)	15,011 (61.7)		1,906 (61.8)	951 (63.2)	955 (60.5)
≥ 60	9,021 (17.2)	3,522 (12.5)	5,499 (22.6)		720 (23.3)	278 (18.5)	442 (27.9)
Income at BC diagnosis
Medical Aid	1,156 (2.2)	440 (1.6)	716 (3.0)	< 0.001	79 (2.6)	26 (1.8)	53 (3.4)	0.013
Top 11%–100%	42,131 (81.4)	22,529 (81.1)	19,602 (81.7)		2,452 (80.5)	1,202 (80.7)	1,250 (80.2)
Top 1%–10%	8,492 (16.4)	4,811 (17.3)	3,681 (15.3)		517 (16.9)	261 (17.5)	256 (16.4)
Systemic Tx at BC diagnosis
None	5,750 (10.9)	1,255 (4.5)	4,495 (18.5)	< 0.001	315 (10.2)	52 (3.5)	263 (16.7)	< 0.001
CTx alone	12,482 (23.8)	7,153 (25.4)	5,329 (21.9)		679 (22.0)	382 (25.4)	297 (18.8)
ETx alone	10,537 (20.1)	5,632 (19.9)	4,905 (20.2)		608 (19.7)	291 (19.3)	317 (20.1)
CTx+ETx	23,737 (45.2)	14,144 (50.2)	9,593 (39.4)		1,482 (48.1)	779 (51.8)	703 (44.4)
SNBPC
None	49,422 (94.1)	26,680 (94.7)	22,742 (93.5)	< 0.001	3,084 (100)	1,504 (100)	1,580 (100)	-
Yes	3,084 (5.9)	1,504 (5.3)	1,580 (6.5)
Interval from BC to SNBPC (yr)
≥ 5 and< 8	1,736 (3.4)	843 (3.0)	893 (3.7)	0.012	1,736 (56.3)	843 (56.1)	893 (56.5)	0.012
≥ 8 and < 11	1,047 (1.9)	536 (1.9)	511 (2.1)		1,047 (33.9)	536 (35.6)	511 (32.3)
≥ 11 and < 14	301 (0.7)	125 (0.5)	176 (0.7)		301 (9.8)	125 (8.3)	176 (11.2)
Types of SNBPC
Head and neck	79 (0.2)	40 (0.1)	39 (0.2)	0.149	79 (2.6)	40 (2.7)	39 (2.5)	0.149
Gastrointestinal	580 (1.1)	262 (0.9)	318 (1.3)		580 (18.8)	262 (17.4)	318 (20.1)
Hepatobiliary	385 (0.8)	180 (0.6)	205 (0.8)		385 (12.5)	180 (11.9)	205 (12.9)
Thoracic	374 (0.8)	188 (0.7)	191 (0.8)		374 (12.1)	188 (12.5)	191 (12.1)
Gynecological	394 (0.8)	208 (0.7)	186 (0.8)		394 (12.8)	208 (13.8)	186 (11.8)
Urologic	78 (0.1)	43 (0.2)	35 (0.1)		78 (2.5)	43 (2.9)	35 (2.2)
Brain	97 (0.2)	54 (0.2)	43 (0.2)		97 (3.2)	54 (3.6)	43 (2.7)
Thyroid	581 (1.1)	264 (0.9)	317 (1.3)		581 (18.8)	264 (17.5)	317 (20.1)
Bone/Soft tissue/Nerve	137 (0.3)	76 (0.3)	61 (0.3)		137 (4.4)	76 (5.1)	61 (3.9)
Skin cancer	130 (0.2)	69 (0.2)	61 (0.3)		130 (4.2)	69 (4.6)	61 (3.9)
Lymphoma/Leukemia	126 (0.2)	60 (0.2)	66 (0.3)		126 (4.1)	60 (3.9)	66 (4.2)
Others	118 (0.2)	60 (0.2)	58 (0.2)		118 (3.8)	60 (3.9)	58 (3.7)
Category of SNBPC^c)
Category A	615 (1.3)	291 (1.0)	324 (1.3)	0.681	615 (19.9)	291 (19.4)	324 (20.5)	0.681
Category B	126 (0.2)	60 (0.2)	66 (0.3)		126 (4.1)	60 (3.9)	66 (4.2)
Category C	2,343 (4.5)	1,153 (4.1)	1,190 (4.9)		2,343 (75.9)	1,153 (76.7)	1,190 (75.3)

Values are presented as median (IQR), mean±SD, or number (%). BC, breast cancer; CTx, chemotherapy; ETx, endocrine therapy; FU, follow-up; IQR, interquartile range; RT, radiotherapy; SD, standard deviation; SNBPC, second non-breast primary cancer; Tx, therapy.

^a) Percentage among all 52,506 women,

^b) Percentage among women with second non-breast primary cancer,

^c) Category A: cancer in intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs other than the stomach.

Table 4

The incidence rate of second non-breast primary cancer^a) depending on variables

Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	10-Year rate (%) (95% CI)	Unadjusted		Adjusted
Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	10-Year rate (%) (95% CI)	HR (95% CI)	p-value	HR (95% CI)	p-value
Total	52,506	3,084	5.78 (5.56–6.00)	-	-	-	-
Age (yr)
< 30	988	46	4.61 (3.19–6.04)	1 (reference)	< 0.001^b)	1 (reference)	< 0.001
30–39	7,881	412	5.12 (4.58–5.65)	1.19 (0.88–1.62)	0.260	1.09 (0.80–1.48)	0.582
40–59	34,616	1,906	5.32 (5.06–5.58)	1.27 (0.95–1.70)	0.108	1.14 (0.85–1.54)	0.373
≥ 60	9,021	720	8.51 (7.84–9.18)	2.15 (1.60–2.90)	< 0.001	1.94 (1.44–2.63)	< 0.001
Level of household income
Medical Aid Program	1,156	79	8.79 (6.73–10.85)	1 (reference)	< 0.001^b)	1 (reference)	0.004
Top 11%–100%	42,131	2,452	5.73 (5.48–5.97)	0.59 (0.47–0.74)	< 0.001	0.68 (0.54–0.85)	0.001
Top 1%–10%	8,492	517	5.74 (5.20–6.28)	0.60 (0.47–0.76)	< 0.001	0.69 (0.54–0.87)	0.002
Adjuvant systemic treatment
None	5,750	315	5.04 (4.43–5.64)	1 (reference)	0.0012^b)	1 (reference)	< 0.001
CTx alone	12,482	679	5.77 (5.30–6.23)	1.19 (1.04–1.36)	0.011	1.23 (1.06–1.42)	0.008
ETx alone	10,537	608	5.52 (5.04–5.99)	1.16 (1.01–1.33)	0.033	1.14 (0.99–1.33)	0.074
CTx+ETx	23,737	1,482	6.09 (5.75–6.42)	1.27 (1.12–1.43)	< 0.001	1.46 (1.28–1.67)	< 0.001
Radiotherapy
No	24,322	1,580	6.23 (5.89–6.56)	1 (reference)	-	1 (reference)	-
Yes	28,184	1,504	5.39 (5.09–5.68)	0.87 (0.81–0.94)	< 0.001	0.89 (0.83–0.96)	0.002

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio.

^a) Second non-breast primary cancer that occurred 5 years or more after a primary BC diagnosis,

^b) p-value of among all groups.

Table 5

Survivals after second non-breast primary cancer diagnosis

Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	5-Year OS (%) (95% CI)	Unadjusted		Adjusted
Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	5-Year OS (%) (95% CI)	HR (95% CI)	p-value	HR (95% CI)	p-value
Total	3,084	1,010	67.28 (65.53–69.02)	-	-	-	-
Age (yr)
< 30	46	16	66.99 (53.26–80.72)	1 (reference)	< 0.001^a)	1 (reference)	< 0.001
30–39	412	134	66.61 (61.68–71.55)	0.88 (0.52–1.48)	0.631	0.85 (0.50–1.42)	0.532
40–59	1,906	515	72.89 (70.79–74.99)	0.68 (0.42–1.13)	0.135	0.67 (0.41–1.10)	0.115
≥ 60	720	345	52.78 (48.95–56.61)	1.46 (0.88–2.40)	0.142	1.54 (0.93–2.54)	0.095
Level of household income
Medical Aid program	79	33	57.31 (45.36–69.25)	1 (reference)	0.070^a)	1 (reference)	0.138
Top 11%–100%	2,452	805	66.99 (65.03–68.95)	0.70 (0.49–0.99)	0.044	0.73 (0.51–1.03)	0.077
Top 1%–10%	517	159	70.51 (66.38–74.64)	0.64 (0.44–0.94)	0.022	0.68 (0.47–0.99)	0.046
Adjuvant systemic treatment
None	315	74	77.46 (72.68–82.23)	1 (reference)	0.000^a)	1 (reference)	< 0.001
CTx alone	679	230	66.00 (62.24–69.77)	1.57 (1.21–2.04)	0.001	1.45 (1.08–1.96)	0.015
ETx alone	608	184	69.83 (65.99–73.68)	1.37 (1.04–1.79)	0.023	1.19 (0.88–1.60)	0.257
CTx+ETx	1,482	522	64.60 (62.03–67.18)	1.64 (1.28–2.09)	< 0.001	1.85 (1.41–2.43)	< 0.001
Radiotherapy
No	1,580	510	68.28 (65.89–70.68)	1 (reference)	0.241^a)	1 (reference)	-
Yes	1,504	500	66.19 (63.64–68.74)	1.08 (0.95–1.22)	-	1.09 (0.96–1.24)	0.201

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio; OS, overall survival.

^a) p-value of among all groups.

Table 6

Literature on the incidence of subsequent primary cancer among survivors of breast cancer

Studies	Inclusion years	No. of BC	Median FU (yr)	Cohort	Incidence of SPC	Definition of SPC	Factors associated with the risk of SPC
National registry
Li et al. [13]	1990–2010	250,764	NA	US, SEER, females with stage I–III BC, 20–80 years old	10 yr: 7.4% 15 yr: 14.4% 20 yr: 20.1%	SPC occurred > 5 yr after BC diagnosis	Increased risk by RT: lung, BC, AML Decreased risk by CTx: lung, BC, leukemia Decreased risk, in HR+ BC: BC, ovary
Sung et al. [14]	1992–2015	431,222	8.4	US, SEER, females with stage I–IV BC, 20–84 years old	HR (+): 11.6% HR (−): 12.3%	SPC occurred > 1 yr after BC diagnosis Included 2nd BC	Different SIR according to the age of onset and HR positivity
Jabagi et al. [16]	2007–2015	122,373	NA	France, National Health Data System, BC received surgery, 20–85 years old	2nd hematologic cancer 0.6%	2nd hematologic cancer occurred > 1 yr after BC surgery	Non-significant increase in the risk of AML, MDS, ALL in CTx+G-CSF than CTx alone
Lin et al. [6]	1998–2007	2,422	4.0	Taiwan national cohort, case-control matching (BC and healthy population)	4 yr: 2.1%	SPC occurred within 4-year after BC registration Excluded 2nd BC	RT was associated with an increased risk of SPC
Grantzau et al. [7]	1982–2007	46,176	NA	Denmark, DBCG national population data, early BC	5.1%	SPC occurred > 1 yr after BC diagnosis Excluded 2nd BC	Increased risk of cancers in RT-associated sites No risk for years in non-RT–associated sites
Silverman et al. [8]	1992–2006	46,090	8.3–8.9	Israel National Cancer Registry	5 yr: 3.6% 10 yr: 8.2% 15 yr: 13.9%	SPC occurred after BC diagnosis Excluded 2nd BC	SIR was 1.26 (95% CI, 1.23–1.30) Women < 50 yr had a greater SIR than women ≥ 50 yr (1.77 vs. 1.20)
Regional registry
Roychoudhuri et al. [17]	1961–2000	64,782	NA	The Thames Cancer Registry, UK, women with breast cancer treated with RT (n=33,763) and without RT (n=31,019)	8.1%	SPC occurred after BC diagnosis	RT was associated with the risk of lung cancer (at 10–14 yr and 15+ yr after RT), Included 2nd BC myeloid leukemia (1–5 yr after RT), esophageal cancer (15+ yr after RT)
Schaapveld et al. [18]	1989–2003	58,068	5.4	The Northwestern and the southeastern part of the Netherlands (46% of the Dutch population)	10 yr: 5.4%	SPC occurred after BC diagnosis Included 2nd BC	Women < 50 yr: RT was associated with increased risk of lung ca; CTx was associated with decreased risk of all cancer Women ≥ 50 yr: RT was associated with the risk of STS; CTx was associated with melanoma, uterine ca, and AML
Molina-Montes et al. [19]	1985–2007	5,897	NA	Southern Spain (Granada Cancer Registry), comparison the risk of SPC in BC (n=5,897) and other cancer (n=22,814)	5.3% (n=314)	SPC occurred after BC diagnosis Excluded 2nd BC	SIR was increased in BC patients than in those with other primary cancer Young women: high SIR for ovarian cancer. old women: high SIR for endometrial cancer
Institutional registry
Zhang et al. [9]	1965–1994	5,248	8.0	The University of Florence, BC patients treated with surgery	2.4% (n=126)	SPC occurred > 1 yr after BC diagnosis Excluded 2nd BC	Risk of leukemia and other SPC was elevated by RT
Kirova et al. [10]	1981–1997	16,705	10.5	Institute of Curie, BC patients treated with RT (n=13,472) and without RT (n=3,233)	In all: 4.2% In RT (+): 4.4% In RT (−): 3.4%	SPC occurred after BC treatment Excluded 2nd BC	RT was significantly related to the risk of sarcoma and lung cancers Other types of SPC were not related to RT-
Meta-analysis
Molina-Montes et al. [11]	Studies published before 2013	2,712,648	NA	Meta-analysis of 15 studies	-	Excluded 2nd BC	SIR for SPC was 1.17 SIR 1.51 in women < 50 yr vs. 1.11 in women ≥ 50 yr SIR 1.19, < 10 yr after BC diagnosis SIR 1.26, ≥ 10 yr after BC diagnosis
Grantzau et al. [12]	Studies published before 2013	762,468	NA	Meta-analysis of 13 studies, risk of SPC after RT	-	Excluded 2nd BC	RT was associated with the risk of SPC (lung, esophagus, and sarcoma) The risk of SPC was highest ≥ 15 yr after BC diagnosis
The current study	2003–2008	52,506	12.1	Korean population data (covers over 98% of the whole population of Korea)	10 yr: 5.78%	SPC occurred ≥ 5 yr after BC diagnosis Excluded 2nd BC	SPC incidence was higher in women with older age, low income, and CTx/ETx RT was associated with lower SPC incidence

ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CI, confidence interval; CTx, chemotherapy; DBCG, the Danish Breast Cancer Cooperative Group; ETx, endocrine therapy; FU, follow-up; G-CSF, granulocyte colony-stimulating factor; HR; hormone receptor; MDS, myelodysplastic syndrome; NA, not available; RT, radiotherapy; SEER, Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio; SPC, subsequent primary cancer; STS, soft tissue sarcoma.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article PubMed PDF
2. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and Prevalence in 2017. Cancer Res Treat. 2020;52:335–50. Article PubMed PMC PDF
3. Ministry of Health and Welfare. Central Cancer Registry. The national cancer registry statistics in 2019 [Internet]. Sejong: Ministry of Health and Welfare; c2020. [cited 2020 May 10]. Available from: http://www.mohw.go.kr
4. Kang SY, Lee SB, Kim YS, Kim Z, Kim HY, Kim HJ, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer. 2021;24:123–37. Article PubMed PMC PDF
5. Moore HC. Breast cancer survivorship. Semin Oncol. 2020;47:222–8. Article PubMed
6. Lin CY, Chen SH, Huang CC, Weng SF, Lee ST, Guo HR, et al. Risk of secondary cancers in women with breast cancer and the influence of radiotherapy: a national cohort study in Taiwan. Medicine (Baltimore). 2016;95:e5556.PubMed PMC
7. Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol. 2013;106:42–9. Article PubMed
8. Silverman BG, Lipshitz I, Keinan-Boker L. Second primary cancers after primary breast cancer diagnosis in Israeli women, 1992 to 2006. J Glob Oncol. 2017;3:135–42. Article PubMed PMC
9. Zhang W, Becciolini A, Biggeri A, Pacini P, Muirhead CR. Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy. Breast Cancer Res. 2011;13:R38.Article PubMed PMC PDF
10. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007;68:359–63. Article PubMed
11. Molina-Montes E, Requena M, Sanchez-Cantalejo E, Fernandez MF, Arroyo-Morales M, Espin J, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol. 2015;136:158–71. Article PubMed
12. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 2015;114:56–65. Article PubMed
13. Li D, Weng S, Zhong C, Tang X, Zhu N, Cheng Y, et al. Risk of second primary cancers among long-term survivors of breast cancer. Front Oncol. 2019;9:1426.Article PubMed PMC
14. Sung H, Freedman RA, Siegel RL, Hyun N, DeSantis CE, Ruddy KJ, et al. Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. Cancer. 2021;127:3310–24. Article PubMed PDF
15. Kim S, Kim MS, You SH, Jung SY. Conducting and reporting a clinical research using Korean Healthcare Claims Database. Korean J Fam Med. 2020;41:146–52. Article PubMed PMC PDF
16. Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: a nationwide population-based cohort. Int J Cancer. 2021;148:375–84. Article PubMed PDF
17. Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004;91:868–72. Article PubMed PMC PDF
18. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26:1239–46. Article PubMed
19. Molina-Montes E, Pollan M, Payer T, Molina E, Davila-Arias C, Sanchez MJ. Risk of second primary cancer among women with breast cancer: a population-based study in Granada (Spain). Gynecol Oncol. 2013;130:340–5. Article PubMed
20. Fiorino C, Guckemberger M, Schwarz M, van der Heide UA, Heijmen B. Technology-driven research for radiotherapy innovation. Mol Oncol. 2020;14:1500–13. Article PubMed PMC PDF
21. Ahn E. Introducing big data analysis using data from National Health Insurance Service. Korean J Anesthesiol. 2020;73:205–11. Article PubMed PMC PDF
22. Park S. Medical service utilization and out-of-pocket spending among near-poor National Health Insurance members in South Korea. BMC Health Serv Res. 2021;21:886.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue
Xinyi Liang, Yiwei Qin, Pengwei Li, You Mo, Dawei Chen
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Association of radiotherapy for stage I–III breast cancer survivors and second primary malignant cancers: a population-based study
Jin Shi, Jian Liu, Guo Tian, Daojuan Li, Di Liang, Jun Wang, Yutong He
European Journal of Cancer Prevention.2024; 33(2): 115. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Epidemiology of Second Non-breast Primary Cancers among Survivors of Breast Cancer: A Korean Population–Based Study by the SMARTSHIP Group

Cancer Res Treat. 2023;55(2):580-591. Published online December 27, 2022

DOI: https://doi.org/10.4143/crt.2022.410

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Epidemiology of Second Non-breast Primary Cancers among Survivors of Breast Cancer: A Korean Population–Based Study by the SMARTSHIP Group

Fig. 1 Flowchart of the study. The second non-breast primary cancer (SNBPC) was defined as newly diagnosed non-breast primary cancer that occurred 5 years or more after an initial breast cancer diagnosis. a)Data on mortality were available until December 2018.

Fig. 1

Epidemiology of Second Non-breast Primary Cancers among Survivors of Breast Cancer: A Korean Population–Based Study by the SMARTSHIP Group

Table 1

Cohort’s characteristics (n=52,506)^a)

Variable	No. of patients (%)
Age at BC diagnosis (yr)
< 30	988 (1.9)
30–39	7,881 (15.0)
40–59	34,616 (65.9)
≥ 60	9,021 (17.2)
Level of household income
Medicare	1,156 (2.2)
Top 11%–100%	42,131 (80.2)
Top 1%–10%	8,492 (16.2)
Not available	727 (1.4)
Adjuvant systemic treatment for primary BC
None	5,750 (10.9)
Chemotherapy	12,482 (23.8)
Endocrine therapy	10,537 (20.1)
Chemotherapy and endocrine therapy	23,737 (45.2)
Radiotherapy for primary BC
None	24,322 (46.3)
Yes	28,184 (53.7)

BC, breast cancer.

^a)Characteristics of women included in this study. The patients received curative treatments for invasive BC between January 2003 and December 2008.

Table 2

Details of women who developed second non-breast primary cancer (n=3,084)

Variable	No. of patients (%)
Interval between BC diagnosis and SNBPC diagnosis (yr)
≥ 5 and < 8	1,736 (56.3)
≥ 8 and < 11	1,047 (33.9)
≥ 11 and < 14	301 (9.8)
Types of SNBPC
Head and neck cancer	79 (2.6)
Gastrointestinal cancer	580 (18.8)
Hepatobiliary cancer	385 (12.5)
Thoracic cancer	374 (12.1)
Gynecological cancer	394 (12.9)
Urologic cancer	78 (2.5)
Brain cancer	97 (3.2)
Thyroid cancer	581 (18.9)
Bone/Soft tissue/Nerve cancer	137 (4.4)
Skin cancer	130 (4.2)
Lymphoma or leukemia	126 (4.1)
Others	118 (3.8)
Category of SNBPC^a)
Category A	615 (19.9)
Category B	126 (4.2)
Category C	2,343 (75.9)
Age at primary BC diagnosis (yr)
< 30	46 (1.5)
30–39	412 (13.4)
40–59	1,906 (61.8)
≥ 60	720 (23.5)
Level of household income at primary BC diagnosis
Medical Aid Program	79 (2.6)
Top 11%–100%	2,452 (80.5)
Top 1%–10%	517 (16.9)
Adjuvant systemic treatment for primary BC
None	315 (10.2)
Chemotherapy alone	679 (22.1)
Endocrine therapy alone	608 (19.7)
Chemotherapy and endocrine therapy	1,482 (48.1)
Radiotherapy for primary BC
None	1,580 (51.2)
Yes	1,504 (48.8)

BC, breast cancer; SNBPC, second non-breast primary cancer.

^a)Category A: cancer in the intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in the head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs.

Table 3

Comparisons of patient’s characteristics according to receipt of breast cancer radiotherapy

Variable	Among all patients				Among patients with SNBPC
Variable	Total (n=52,506)	RT (+) (n=28,184)	RT (−) (n=24,322)	p-value	Total (n=3,084)	RT (+) (n=1,504)	RT (−) (n=1,580)	p-value
FU (yr)	12.13 (10.63–13.92)	11.88 (10.56–13.55)	12.47 (10.79–14.28)	< 0.001	12.27 (10.44–14.23)	11.88 (10.32–13.95)	12.59 (10.63–14.49)	< 0.001
Age (yr)	49.14±10.71	47.88±9.52	50.59 (11.77)	< 0.001	50.68±11.13	48.95±10.57	52.32±11.4	< 0.001
Age at BC diagnosis (yr)
< 30	988 (1.9)^a)	498 (1.8)	490 (2.0)	< 0.001	46 (1.5)^b)	34 (2.3)	12 (0.8)	< 0.001
30–39	7,881 (15.0)	4,559 (16.2)	3,322 (13.7)		412 (13.4)	241 (16.0)	171 (10.8)
40–59	34,616 (65.9)	19,605 (69.5)	15,011 (61.7)		1,906 (61.8)	951 (63.2)	955 (60.5)
≥ 60	9,021 (17.2)	3,522 (12.5)	5,499 (22.6)		720 (23.3)	278 (18.5)	442 (27.9)
Income at BC diagnosis
Medical Aid	1,156 (2.2)	440 (1.6)	716 (3.0)	< 0.001	79 (2.6)	26 (1.8)	53 (3.4)	0.013
Top 11%–100%	42,131 (81.4)	22,529 (81.1)	19,602 (81.7)		2,452 (80.5)	1,202 (80.7)	1,250 (80.2)
Top 1%–10%	8,492 (16.4)	4,811 (17.3)	3,681 (15.3)		517 (16.9)	261 (17.5)	256 (16.4)
Systemic Tx at BC diagnosis
None	5,750 (10.9)	1,255 (4.5)	4,495 (18.5)	< 0.001	315 (10.2)	52 (3.5)	263 (16.7)	< 0.001
CTx alone	12,482 (23.8)	7,153 (25.4)	5,329 (21.9)		679 (22.0)	382 (25.4)	297 (18.8)
ETx alone	10,537 (20.1)	5,632 (19.9)	4,905 (20.2)		608 (19.7)	291 (19.3)	317 (20.1)
CTx+ETx	23,737 (45.2)	14,144 (50.2)	9,593 (39.4)		1,482 (48.1)	779 (51.8)	703 (44.4)
SNBPC
None	49,422 (94.1)	26,680 (94.7)	22,742 (93.5)	< 0.001	3,084 (100)	1,504 (100)	1,580 (100)	-
Yes	3,084 (5.9)	1,504 (5.3)	1,580 (6.5)
Interval from BC to SNBPC (yr)
≥ 5 and< 8	1,736 (3.4)	843 (3.0)	893 (3.7)	0.012	1,736 (56.3)	843 (56.1)	893 (56.5)	0.012
≥ 8 and < 11	1,047 (1.9)	536 (1.9)	511 (2.1)		1,047 (33.9)	536 (35.6)	511 (32.3)
≥ 11 and < 14	301 (0.7)	125 (0.5)	176 (0.7)		301 (9.8)	125 (8.3)	176 (11.2)
Types of SNBPC
Head and neck	79 (0.2)	40 (0.1)	39 (0.2)	0.149	79 (2.6)	40 (2.7)	39 (2.5)	0.149
Gastrointestinal	580 (1.1)	262 (0.9)	318 (1.3)		580 (18.8)	262 (17.4)	318 (20.1)
Hepatobiliary	385 (0.8)	180 (0.6)	205 (0.8)		385 (12.5)	180 (11.9)	205 (12.9)
Thoracic	374 (0.8)	188 (0.7)	191 (0.8)		374 (12.1)	188 (12.5)	191 (12.1)
Gynecological	394 (0.8)	208 (0.7)	186 (0.8)		394 (12.8)	208 (13.8)	186 (11.8)
Urologic	78 (0.1)	43 (0.2)	35 (0.1)		78 (2.5)	43 (2.9)	35 (2.2)
Brain	97 (0.2)	54 (0.2)	43 (0.2)		97 (3.2)	54 (3.6)	43 (2.7)
Thyroid	581 (1.1)	264 (0.9)	317 (1.3)		581 (18.8)	264 (17.5)	317 (20.1)
Bone/Soft tissue/Nerve	137 (0.3)	76 (0.3)	61 (0.3)		137 (4.4)	76 (5.1)	61 (3.9)
Skin cancer	130 (0.2)	69 (0.2)	61 (0.3)		130 (4.2)	69 (4.6)	61 (3.9)
Lymphoma/Leukemia	126 (0.2)	60 (0.2)	66 (0.3)		126 (4.1)	60 (3.9)	66 (4.2)
Others	118 (0.2)	60 (0.2)	58 (0.2)		118 (3.8)	60 (3.9)	58 (3.7)
Category of SNBPC^c)
Category A	615 (1.3)	291 (1.0)	324 (1.3)	0.681	615 (19.9)	291 (19.4)	324 (20.5)	0.681
Category B	126 (0.2)	60 (0.2)	66 (0.3)		126 (4.1)	60 (3.9)	66 (4.2)
Category C	2,343 (4.5)	1,153 (4.1)	1,190 (4.9)		2,343 (75.9)	1,153 (76.7)	1,190 (75.3)

^a)Percentage among all 52,506 women,

^b)Percentage among women with second non-breast primary cancer,

^c)Category A: cancer in intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs other than the stomach.

Table 4

The incidence rate of second non-breast primary cancer^a) depending on variables

Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	10-Year rate (%) (95% CI)	Unadjusted		Adjusted
Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	10-Year rate (%) (95% CI)	HR (95% CI)	p-value	HR (95% CI)	p-value
Total	52,506	3,084	5.78 (5.56–6.00)	-	-	-	-
Age (yr)
< 30	988	46	4.61 (3.19–6.04)	1 (reference)	< 0.001^b)	1 (reference)	< 0.001
30–39	7,881	412	5.12 (4.58–5.65)	1.19 (0.88–1.62)	0.260	1.09 (0.80–1.48)	0.582
40–59	34,616	1,906	5.32 (5.06–5.58)	1.27 (0.95–1.70)	0.108	1.14 (0.85–1.54)	0.373
≥ 60	9,021	720	8.51 (7.84–9.18)	2.15 (1.60–2.90)	< 0.001	1.94 (1.44–2.63)	< 0.001
Level of household income
Medical Aid Program	1,156	79	8.79 (6.73–10.85)	1 (reference)	< 0.001^b)	1 (reference)	0.004
Top 11%–100%	42,131	2,452	5.73 (5.48–5.97)	0.59 (0.47–0.74)	< 0.001	0.68 (0.54–0.85)	0.001
Top 1%–10%	8,492	517	5.74 (5.20–6.28)	0.60 (0.47–0.76)	< 0.001	0.69 (0.54–0.87)	0.002
Adjuvant systemic treatment
None	5,750	315	5.04 (4.43–5.64)	1 (reference)	0.0012^b)	1 (reference)	< 0.001
CTx alone	12,482	679	5.77 (5.30–6.23)	1.19 (1.04–1.36)	0.011	1.23 (1.06–1.42)	0.008
ETx alone	10,537	608	5.52 (5.04–5.99)	1.16 (1.01–1.33)	0.033	1.14 (0.99–1.33)	0.074
CTx+ETx	23,737	1,482	6.09 (5.75–6.42)	1.27 (1.12–1.43)	< 0.001	1.46 (1.28–1.67)	< 0.001
Radiotherapy
No	24,322	1,580	6.23 (5.89–6.56)	1 (reference)	-	1 (reference)	-
Yes	28,184	1,504	5.39 (5.09–5.68)	0.87 (0.81–0.94)	< 0.001	0.89 (0.83–0.96)	0.002

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio.

^a)Second non-breast primary cancer that occurred 5 years or more after a primary BC diagnosis,

^b)p-value of among all groups.

Table 5

Survivals after second non-breast primary cancer diagnosis

Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	5-Year OS (%) (95% CI)	Unadjusted		Adjusted
Characteristics at the time of primary BC diagnosis	No. of patients	No. of events	5-Year OS (%) (95% CI)	HR (95% CI)	p-value	HR (95% CI)	p-value
Total	3,084	1,010	67.28 (65.53–69.02)	-	-	-	-
Age (yr)
< 30	46	16	66.99 (53.26–80.72)	1 (reference)	< 0.001^a)	1 (reference)	< 0.001
30–39	412	134	66.61 (61.68–71.55)	0.88 (0.52–1.48)	0.631	0.85 (0.50–1.42)	0.532
40–59	1,906	515	72.89 (70.79–74.99)	0.68 (0.42–1.13)	0.135	0.67 (0.41–1.10)	0.115
≥ 60	720	345	52.78 (48.95–56.61)	1.46 (0.88–2.40)	0.142	1.54 (0.93–2.54)	0.095
Level of household income
Medical Aid program	79	33	57.31 (45.36–69.25)	1 (reference)	0.070^a)	1 (reference)	0.138
Top 11%–100%	2,452	805	66.99 (65.03–68.95)	0.70 (0.49–0.99)	0.044	0.73 (0.51–1.03)	0.077
Top 1%–10%	517	159	70.51 (66.38–74.64)	0.64 (0.44–0.94)	0.022	0.68 (0.47–0.99)	0.046
Adjuvant systemic treatment
None	315	74	77.46 (72.68–82.23)	1 (reference)	0.000^a)	1 (reference)	< 0.001
CTx alone	679	230	66.00 (62.24–69.77)	1.57 (1.21–2.04)	0.001	1.45 (1.08–1.96)	0.015
ETx alone	608	184	69.83 (65.99–73.68)	1.37 (1.04–1.79)	0.023	1.19 (0.88–1.60)	0.257
CTx+ETx	1,482	522	64.60 (62.03–67.18)	1.64 (1.28–2.09)	< 0.001	1.85 (1.41–2.43)	< 0.001
Radiotherapy
No	1,580	510	68.28 (65.89–70.68)	1 (reference)	0.241^a)	1 (reference)	-
Yes	1,504	500	66.19 (63.64–68.74)	1.08 (0.95–1.22)	-	1.09 (0.96–1.24)	0.201

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio; OS, overall survival.

^a)p-value of among all groups.

Table 6

Literature on the incidence of subsequent primary cancer among survivors of breast cancer

Studies	Inclusion years	No. of BC	Median FU (yr)	Cohort	Incidence of SPC	Definition of SPC	Factors associated with the risk of SPC
National registry
Li et al. [13]	1990–2010	250,764	NA	US, SEER, females with stage I–III BC, 20–80 years old	10 yr: 7.4% 15 yr: 14.4% 20 yr: 20.1%	SPC occurred > 5 yr after BC diagnosis	Increased risk by RT: lung, BC, AML Decreased risk by CTx: lung, BC, leukemia Decreased risk, in HR+ BC: BC, ovary
Sung et al. [14]	1992–2015	431,222	8.4	US, SEER, females with stage I–IV BC, 20–84 years old	HR (+): 11.6% HR (−): 12.3%	SPC occurred > 1 yr after BC diagnosis Included 2nd BC	Different SIR according to the age of onset and HR positivity
Jabagi et al. [16]	2007–2015	122,373	NA	France, National Health Data System, BC received surgery, 20–85 years old	2nd hematologic cancer 0.6%	2nd hematologic cancer occurred > 1 yr after BC surgery	Non-significant increase in the risk of AML, MDS, ALL in CTx+G-CSF than CTx alone
Lin et al. [6]	1998–2007	2,422	4.0	Taiwan national cohort, case-control matching (BC and healthy population)	4 yr: 2.1%	SPC occurred within 4-year after BC registration Excluded 2nd BC	RT was associated with an increased risk of SPC
Grantzau et al. [7]	1982–2007	46,176	NA	Denmark, DBCG national population data, early BC	5.1%	SPC occurred > 1 yr after BC diagnosis Excluded 2nd BC	Increased risk of cancers in RT-associated sites No risk for years in non-RT–associated sites
Silverman et al. [8]	1992–2006	46,090	8.3–8.9	Israel National Cancer Registry	5 yr: 3.6% 10 yr: 8.2% 15 yr: 13.9%	SPC occurred after BC diagnosis Excluded 2nd BC	SIR was 1.26 (95% CI, 1.23–1.30) Women < 50 yr had a greater SIR than women ≥ 50 yr (1.77 vs. 1.20)
Regional registry
Roychoudhuri et al. [17]	1961–2000	64,782	NA	The Thames Cancer Registry, UK, women with breast cancer treated with RT (n=33,763) and without RT (n=31,019)	8.1%	SPC occurred after BC diagnosis	RT was associated with the risk of lung cancer (at 10–14 yr and 15+ yr after RT), Included 2nd BC myeloid leukemia (1–5 yr after RT), esophageal cancer (15+ yr after RT)
Schaapveld et al. [18]	1989–2003	58,068	5.4	The Northwestern and the southeastern part of the Netherlands (46% of the Dutch population)	10 yr: 5.4%	SPC occurred after BC diagnosis Included 2nd BC	Women < 50 yr: RT was associated with increased risk of lung ca; CTx was associated with decreased risk of all cancer Women ≥ 50 yr: RT was associated with the risk of STS; CTx was associated with melanoma, uterine ca, and AML
Molina-Montes et al. [19]	1985–2007	5,897	NA	Southern Spain (Granada Cancer Registry), comparison the risk of SPC in BC (n=5,897) and other cancer (n=22,814)	5.3% (n=314)	SPC occurred after BC diagnosis Excluded 2nd BC	SIR was increased in BC patients than in those with other primary cancer Young women: high SIR for ovarian cancer. old women: high SIR for endometrial cancer
Institutional registry
Zhang et al. [9]	1965–1994	5,248	8.0	The University of Florence, BC patients treated with surgery	2.4% (n=126)	SPC occurred > 1 yr after BC diagnosis Excluded 2nd BC	Risk of leukemia and other SPC was elevated by RT
Kirova et al. [10]	1981–1997	16,705	10.5	Institute of Curie, BC patients treated with RT (n=13,472) and without RT (n=3,233)	In all: 4.2% In RT (+): 4.4% In RT (−): 3.4%	SPC occurred after BC treatment Excluded 2nd BC	RT was significantly related to the risk of sarcoma and lung cancers Other types of SPC were not related to RT-
Meta-analysis
Molina-Montes et al. [11]	Studies published before 2013	2,712,648	NA	Meta-analysis of 15 studies	-	Excluded 2nd BC	SIR for SPC was 1.17 SIR 1.51 in women < 50 yr vs. 1.11 in women ≥ 50 yr SIR 1.19, < 10 yr after BC diagnosis SIR 1.26, ≥ 10 yr after BC diagnosis
Grantzau et al. [12]	Studies published before 2013	762,468	NA	Meta-analysis of 13 studies, risk of SPC after RT	-	Excluded 2nd BC	RT was associated with the risk of SPC (lung, esophagus, and sarcoma) The risk of SPC was highest ≥ 15 yr after BC diagnosis
The current study	2003–2008	52,506	12.1	Korean population data (covers over 98% of the whole population of Korea)	10 yr: 5.78%	SPC occurred ≥ 5 yr after BC diagnosis Excluded 2nd BC	SPC incidence was higher in women with older age, low income, and CTx/ETx RT was associated with lower SPC incidence

Table 1 Cohort’s characteristics (n=52,506)a)

BC, breast cancer.

Characteristics of women included in this study. The patients received curative treatments for invasive BC between January 2003 and December 2008.

Table 2 Details of women who developed second non-breast primary cancer (n=3,084)

BC, breast cancer; SNBPC, second non-breast primary cancer.

Category A: cancer in the intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in the head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs.

Table 3 Comparisons of patient’s characteristics according to receipt of breast cancer radiotherapy

Percentage among all 52,506 women,

Percentage among women with second non-breast primary cancer,

Category A: cancer in intrathoracic organs, thyroid, esophagus, or stomach; category B: cancer of hematopoietic or lymphoid tissue; and category C: cancer in head and neck region, skin, female reproductive organs, urinary tract, central nervous system, endocrine gland, or digestive organs other than the stomach.

Table 4 The incidence rate of second non-breast primary cancera) depending on variables

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio.

Second non-breast primary cancer that occurred 5 years or more after a primary BC diagnosis,

p-value of among all groups.

Table 5 Survivals after second non-breast primary cancer diagnosis

BC, breast cancer; CI, confidence interval; CTx, chemotherapy; ETx, endocrine therapy; HR, hazard ratio; OS, overall survival.

p-value of among all groups.

Table 6 Literature on the incidence of subsequent primary cancer among survivors of breast cancer